期刊
JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS
卷 40, 期 11, 页码 1412-1416出版社
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10803-010-0988-9
关键词
Acamprosate; Fragile X syndrome; mGluR5; Language; Irritability
资金
- NCRR NIH HHS [K12 UL1 RR025761] Funding Source: Medline
- NIMH NIH HHS [R01 MH072964] Funding Source: Medline
Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). We report on the first trial of acamprosate, a drug with putative mGluR5 antagonism, in three adults with FXS and autism. Medical records describing open-label treatment with acamprosate in 3 patients with FXS and a comorbid diagnosis of autistic disorder were reviewed. In all three patients, acamprosate was associated with improved linguistic communication. Three patients received acamprosate over a mean 21.3 weeks of treatment. All patients showed global clinical benefit as rated with the Clinical Global Impressions-Improvement scale. Marked communication improvement was unexpected and has potential implications for the treatment of FXS, as well as idiopathic autism.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据